Supplemental material
Open access
3,391
Views
0
CrossRef citations to date
0
Altmetric
Report
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties
Abdullah Elsayeda Philochem AG, Libernstrasse 3, Otelfingen, Switzerland;b Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerlandhttps://orcid.org/0000-0001-7080-0853View further author information
, Christian Pellegrinoc Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerlandhttps://orcid.org/0000-0001-7898-9988View further author information
, Louis Plüssa Philochem AG, Libernstrasse 3, Otelfingen, Switzerland;b Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, SwitzerlandView further author information
, Frederik Peisserta Philochem AG, Libernstrasse 3, Otelfingen, SwitzerlandView further author information
, Ramon Benzb Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, SwitzerlandView further author information
, Franziska Ulrichb Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, SwitzerlandView further author information
, Gudrun Thorhallsdottira Philochem AG, Libernstrasse 3, Otelfingen, Switzerland;b Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerlandhttps://orcid.org/0009-0005-0604-7728View further author information
, Sheila Dakhel Plazaa Philochem AG, Libernstrasse 3, Otelfingen, SwitzerlandView further author information
, Alessandra Villaa Philochem AG, Libernstrasse 3, Otelfingen, SwitzerlandView further author information
, Jacqueline Mocka Philochem AG, Libernstrasse 3, Otelfingen, Switzerlandhttps://orcid.org/0000-0002-4618-1113View further author information
, Emanuele Pucaa Philochem AG, Libernstrasse 3, Otelfingen, Switzerlandhttps://orcid.org/0000-0002-2869-3203View further author information
, Roberto De Lucaa Philochem AG, Libernstrasse 3, Otelfingen, Switzerlandhttps://orcid.org/0000-0001-7519-8689View further author information
, Markus G. Manzc Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerlandhttps://orcid.org/0000-0002-4676-7931View further author information
, Cornelia Halinb Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerlandhttps://orcid.org/0000-0002-7899-2850View further author information
& Dario Neria Philochem AG, Libernstrasse 3, Otelfingen, Switzerland;b Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerland;d Philogen SpA, Siena (S), ItalyCorrespondence[email protected]
https://orcid.org/0000-0001-5234-7370View further author information
show allhttps://orcid.org/0000-0001-5234-7370View further author information
Article: 2220839
|
Received 17 Feb 2023, Accepted 30 May 2023, Published online: 08 Jun 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.